Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
28 11 2022
Historique:
received: 11 06 2022
accepted: 13 09 2022
pubmed: 8 10 2022
medline: 1 12 2022
entrez: 7 10 2022
Statut: ppublish

Résumé

To assess the impact on the estimated glomerular filtration rate (eGFR) of different tenofovir disoproxil/emtricitabine dosing regimens for HIV pre-exposure prophylaxis (PrEP). We included in the study individuals with baseline eGFR > 50 mL/min/1.73 m2 who initiated PrEP in the ongoing ANRS-PREVENIR PrEP cohort. We retrospectively classified PrEP users in three groups: 'on-demand' (reported at ≥75% of study visits), 'daily' (≥75% of study visits) or 'switches'. We compared the area under curve (AUC) of the eGFR variation from baseline (ΔeGFR) between groups using analysis of covariance, and assessed factors associated with a negative AUC of ΔeGFR. From May 2017 to October 2020, 1253 PrEP-naïve participants (98% of MSM) were included in the study with a median follow-up of 22 months. 499 (40%), 494 (39%) and 260 (21%) users were in the group daily, on-demand and switches, respectively, for a median number of pills taken per week of 6, 1.7 and 4. The mean AUC of the ΔeGFR was -1.09 mL/min/1.73 m2 in the daily PrEP group, -0.69 mL/min/1.73 m2 in the switches group and +0.18 mL/min/1.73 m2 with on-demand PrEP. In a model adjusted on baseline age and eGFR, the AUC of the ΔeGFR was significantly higher with on-demand PrEP compared to daily PrEP (P = 0.037). Independent factors associated with a negative AUC of ΔeGFR were a daily PrEP regimen, a switches regimen, an age > 40 years and a baseline eGFR≥90 mL/min/1.73 m². On-demand PrEP dosing had a smaller impact on eGFR evolution than daily PrEP, but the difference was not clinically relevant.

Identifiants

pubmed: 36205009
pii: 6751037
doi: 10.1093/jac/dkac336
doi:

Substances chimiques

Anti-HIV Agents 0
Emtricitabine G70B4ETF4S

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3427-3435

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Geoffroy Liegeon (G)

Service des maladies infectieuses, Assistance publique - Hôpitaux de Paris (AP-HP), Hôpitaux Saint Louis et Lariboisière, Paris 75010, France.
Université Paris Cité, Paris 75006, France.

Lambert Assoumou (L)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris 75646, France.

Jade Ghosn (J)

Université Paris Cité, Paris 75006, France.
Service des maladies infectieuses, AP-HP, Hôpital Bichat, Paris 75018, France.

Mayssam El Mouhebb (M)

Université Paris Cité, Paris 75006, France.

Romain Palich (R)

Service des maladies infectieuse, AP-HP, Hôpital Pitié Salpetrière, Paris 75013, France.

Christia Palacios (C)

Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris 75020, France.

Laurence Slama (L)

Service des maladies infectieuses, AP-HP, Hôpital Hôtel Dieu, Paris 75004, France.

Laure Surgers (L)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris 75646, France.
Service des maladies infectieuses, AP-HP, Hôpital Saint Antoine, Paris 75012, France.

Michèle Genin (M)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris 75646, France.

Lydie Beniguel (L)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris 75646, France.

Lauriane Goldwirt (L)

Service de pharmacologie clinique, AP-HP, Hôpital Saint Louis, Paris 75010, France.

Claudine Duvivier (C)

Service des maladies infectieuses, AP-HP, Hôpital Necker-Enfants Malades, Centre d'Infectiologie Necker Pasteur; IHU Imagine, Paris 75015, France.
Institut Cochin - CNRS 8104 - INSERM U1016 - RIL (Retrovirus, Infection, and Latency) Team, Université Paris Cité, Paris 75014, France.
Institut Pasteur, Centre Médical de l'Institut Pasteur, Paris 75015France.

Daniela Rojas Castro (D)

Association AIDES et Coalition plus, Pantin 93500, France.

Dominique Costagliola (D)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris 75646, France.

Jean-Michel Molina (JM)

Service des maladies infectieuses, Assistance publique - Hôpitaux de Paris (AP-HP), Hôpitaux Saint Louis et Lariboisière, Paris 75010, France.
Université Paris Cité, Paris 75006, France.
INSERM UMR 941, Paris 75010, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH